HHS and Pentagon Statements on FDA Authorization of Moderna Vaccine

U.S. Department of Defense

On Friday, the Food and Drug Administration announced that it had issued an Emergency Use Authorization (EUA) for Moderna's COVID-19 vaccine, the second COVID-19 vaccine to receive an EUA.

Operation Warp Speed has allocated more than 5.9 million doses of the vaccine for jurisdictions to receive in the coming week.

Below are statements from HHS Secretary Alex Azar and Acting Defense Secretary Christopher Miller.

"On January 7, before China had reported even one death from the novel coronavirus or confirmed human-to-human transmission, NIH scientists and innovators at Moderna agreed to begin work on the vaccine that received FDA authorization today.

In March, BARDA scientists joined the partnership and worked with Moderna and NIH to reach commercialization, building on support BARDA has provided since 2016 for the remarkable mRNA technology.

To have two vaccines against a novel virus authorized and distributed within a year is extraordinary, and to have one of these vaccines developed by scientists at the NIH should be a great source of pride for every member of the HHS family and every American.

The public-private partnership of Operation Warp Speed has helped Moderna, an American startup, become one of the first two companies to receive FDA authorization for a COVID-19 vaccine.

Authorization of Moderna's vaccine means we can accelerate the vaccination of frontline healthcare workers and Americans in long-term-care facilities, and, ultimately, bring a faster end to this pandemic." – HHS Secretary Alex Azar

"The swift authorization of a second vaccine by the FDA is great news for the American people.

The DoD, with the work of General Perna and Operation Warp Speed, stands ready to work with our public and private-sector partners to ensure doses reach Americans as soon as possible.

Together, we will bring this pandemic to an end." – Acting Secretary of Defense Christopher Miller

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.